1. Skip to header
  2. Skip to main
  3. Skip to content
  4. Skip to sidebar
  5. Skip to footer
  • Home > Blog > Mesothelioma > U.S. and China Companies Join Forces in Manufacturing Drug for Lung Cancer and Mesothelioma
Posted on Wednesday, Oct 21, 2009

U.S. and China Companies Join Forces in Manufacturing Drug for Lung Cancer and Mesothelioma

Simcere Pharmaceutical Group, a Chinese pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals, has joined forces with OSI Pharmaceuticals, Inc. of the United States, to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

OSI, based in Long Island, NY, specialized in the discovery and development of innovative molecular targeted therapies. OSI-930 targets both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in small cell lung cancer, non-small cell lung cancer, colorectal, gastric and other cancers. The drug is also being tested for the treatment of mesothelioma.

Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals said, “As a leading Chinese pharmaceutical company with a successful track record of developing and commercializing oncology products in China, we are confident that Simcere has the right capabilities and resources to successfully manufacture, develop and market OSI-930 in China.”

According to the World Health Organization, China will have the world’s highest number of lung cancer patients, close to 1 million a year by 2025, if smoking and pollution are not effectively curbed.

Simcere stocks (NYSE: SCR) rose 10% yesterday after the news was announced.

Reference NCT00603356 on ClinicalTrials.gov for further information on OSI-930.